PubMed · 1989 · 18 citations · 0 references
MedicinePharmacologyPsychiatryNeuropharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyNeuropsychiatric PharmacotherapyPsychostimulant PharmacologySchizophrenia PharmacotherapyAnticonvulsant TreatmentAntipsychotic ActionPropranolol TherapyPsychostimulant PharmacotherapyReplication Study Design
Twelve DSM-IIIR diagnosed schizophrenics, with neuroleptic-induced akathisia (NIA), were treated with either propranolol or matched placebo for two days, followed by a treatment crossover phase for five more days. Raters and patients were "blind" to treatment. This study shows that 120 mg of propranolol a day is more effective than placebo in reducing akathisia, and that propranolol's antiakathisic effect may require several days of treatment.